Tomoko Funazo

575 total citations
28 papers, 347 citations indexed

About

Tomoko Funazo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Tomoko Funazo has authored 28 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Tomoko Funazo's work include Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Research Studies (5 papers). Tomoko Funazo is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Research Studies (5 papers). Tomoko Funazo collaborates with scholars based in Japan and United States. Tomoko Funazo's co-authors include Yuichi Sakamori, Hironori Yoshida, Takahiro Tsuji, Hiroaki Ozasa, Takashi Nomizo, Toyohiro Hirai, Yuto Yasuda, Young Hak Kim, Hiroki Nagai and Wataru Aoki and has published in prestigious journals such as Nature Communications, Cancer Research and Scientific Reports.

In The Last Decade

Tomoko Funazo

27 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomoko Funazo Japan 10 223 172 123 62 56 28 347
Takashi Nomizo Japan 11 236 1.1× 175 1.0× 124 1.0× 64 1.0× 57 1.0× 28 354
Yuto Yasuda Japan 10 221 1.0× 172 1.0× 121 1.0× 62 1.0× 59 1.1× 35 346
Wenxian You China 7 130 0.6× 110 0.6× 167 1.4× 111 1.8× 74 1.3× 10 329
Hailing Jin United States 10 103 0.5× 118 0.7× 183 1.5× 100 1.6× 26 0.5× 11 340
Ling Dai China 9 238 1.1× 136 0.8× 105 0.9× 68 1.1× 53 0.9× 28 347
Jodi A. McKenzie United States 8 121 0.5× 73 0.4× 155 1.3× 54 0.9× 81 1.4× 30 302
Tongji Xie China 10 171 0.8× 133 0.8× 113 0.9× 51 0.8× 59 1.1× 41 287
F. R. Hirsch United States 9 247 1.1× 222 1.3× 220 1.8× 71 1.1× 18 0.3× 26 449
Hideo Tomihara Japan 5 129 0.6× 64 0.4× 136 1.1× 60 1.0× 34 0.6× 23 281
Aung Kyi Thar Min Japan 11 226 1.0× 69 0.4× 193 1.6× 104 1.7× 135 2.4× 16 417

Countries citing papers authored by Tomoko Funazo

Since Specialization
Citations

This map shows the geographic impact of Tomoko Funazo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoko Funazo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoko Funazo more than expected).

Fields of papers citing papers by Tomoko Funazo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoko Funazo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoko Funazo. The network helps show where Tomoko Funazo may publish in the future.

Co-authorship network of co-authors of Tomoko Funazo

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoko Funazo. A scholar is included among the top collaborators of Tomoko Funazo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoko Funazo. Tomoko Funazo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yoshida, Hironori, Hiroshi Yoshida, Kazutaka Hosoya, et al.. (2025). Safety and efficacy of pemetrexed for patients with non-small cell lung cancer in the setting of renal impairment: a retrospective study. BMC Cancer. 25(1). 388–388.
2.
Ozasa, Hiroaki, Takahiro Tsuji, Tomoko Funazo, et al.. (2023). Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation–positive Lung Cancer. Molecular Cancer Therapeutics. 23(4). 564–576. 5 indexed citations
3.
Ozasa, Hiroaki, Hironori Yoshida, Takashi Nomizo, et al.. (2023). CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer. Oncology Letters. 26(2). 364–364. 3 indexed citations
4.
Ozasa, Hiroaki, Akihiko Yoshizawa, Hiroshi Yoshida, et al.. (2022). Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series. Oncology Letters. 24(5). 402–402. 1 indexed citations
5.
Ozasa, Hiroaki, Susumu Satô, Tomoko Funazo, et al.. (2021). Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer. Scientific Reports. 11(1). 23677–23677. 14 indexed citations
6.
Funazo, Tomoko, Takahiro Tsuji, Hiroaki Ozasa, et al.. (2020). Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. Molecular Cancer Therapeutics. 19(6). 1320–1327. 5 indexed citations
7.
Yasuda, Yuto, Hiroaki Ozasa, Young Hak Kim, et al.. (2020). MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression. Cell Death and Disease. 11(3). 177–177. 32 indexed citations
8.
Tsuji, Takahiro, Hiroaki Ozasa, Wataru Aoki, et al.. (2020). YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nature Communications. 11(1). 74–74. 57 indexed citations
9.
Yoshida, Hironori, Takashi Nomizo, Hiroaki Ozasa, et al.. (2020). PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade. European Journal of Cancer. 144. 317–325. 13 indexed citations
10.
Funazo, Tomoko, Takashi Nomizo, Hiroaki Ozasa, et al.. (2019). Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Scientific Reports. 9(1). 17085–17085. 13 indexed citations
11.
Tsuji, Takahiro, Hiroaki Ozasa, Wataru Aoki, et al.. (2018). Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. Molecular Cancer Research. 17(1). 212–224. 41 indexed citations
12.
Nomizo, Takashi, Hiroaki Ozasa, Takahiro Tsuji, et al.. (2018). Abstract 2604: PD-L1 rs2282055 is associated with opposite treatment effect between platinum-based chemotherapy and nivolumab treatment. Cancer Research. 78(13_Supplement). 2604–2604. 1 indexed citations
13.
Yasuda, Yuto, Takashi Nomizo, Hiroaki Ozasa, et al.. (2017). Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease. Molecular and Clinical Oncology. 7(4). 677–680. 9 indexed citations
14.
Nomizo, Takashi, Hiroaki Ozasa, Takahiro Tsuji, et al.. (2017). Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. Scientific Reports. 7(1). 45124–45124. 69 indexed citations
15.
Yoshida, Hironori, Young Hak Kim, Hiroaki Ozasa, et al.. (2017). EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. Anticancer Research. 37(5). 2721–2725. 10 indexed citations
16.
Yoshida, Hironori, Hiroaki Ozasa, Hiroki Nagai, et al.. (2017). Nivolumab in non-small-cell lung cancer with EGFR mutation. Annals of Oncology. 29(3). 777–778. 29 indexed citations
17.
Sakamori, Yuichi, Yuto Yasuda, Tomoko Funazo, et al.. (2017). P2.03-055 Comparison of Afatinib Versus Erlotinib for Advanced Non-Small-Cell Lung Cancer Patients with Resistance to EGFR-TKI. Journal of Thoracic Oncology. 12(11). S2396–S2396. 1 indexed citations
18.
Ozasa, Hiroaki, Susumu Satô, Yuichi Sakamori, et al.. (2016). Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer. Annals of Oncology. 27. vi460–vi460. 2 indexed citations
19.
Ariyasu, Ryo, et al.. (2016). Varicella Reinfection with Unilateral Varicella Pneumonia. Internal Medicine. 55(21). 3143–3145. 3 indexed citations
20.
Murakami, Takaaki, Masanori Yoshida, Tomoko Funazo, et al.. (2014). Prolonged Disturbance of Consciousness Caused by Severe Hypophosphatemia: A Report of Two Cases. Internal Medicine. 53(19). 2227–2232. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Takashi Nomizo Breakdown of academic impact, for papers by Yuto Yasuda Breakdown of academic impact, for papers by Wenxian You Breakdown of academic impact, for papers by Hailing Jin Breakdown of academic impact, for papers by Ling Dai Breakdown of academic impact, for papers by Jodi A. McKenzie Breakdown of academic impact, for papers by Tongji Xie Breakdown of academic impact, for papers by F. R. Hirsch Breakdown of academic impact, for papers by Hideo Tomihara Breakdown of academic impact, for papers by Aung Kyi Thar Min
Rankless by CCL
2026